Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
-
Sonnet BioTherapeutics (SONN) Prices 1.11M Share Offering at $4.50/sh
-
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
-
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
-
Sonnet BioTherapeutics (SONN) Announces Review of Strategic Alternatives
-
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
-
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
-
Sonnet BioTherapeutics (SONN) Announces Pricing of $4.55 Million Underwritten Public Offering
-
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
-
Sonnet BioTherapeutics (SONN) Prices 5M Share Offering at $0.45/sh
-
Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
-
Sonnet BioTherapeutics (SONN) Prices $15M Offering of Common Stock, Warrants
-
Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering
-
Sonnet BioTherapeutics (SONN) PT Lowered to $2.50 at Chardan Capital Markets
-
Sonnet BioTherapeutics (SONN) Prices 35.3M Share+Warrant Offering at $0.85/sh
-
Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering
-
Sonnet BioTherapeutics (SONN) Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million
-
Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million
-
Chardan Capital Markets Starts Sonnet BioTherapeutics (SONN) at Buy

